Glaucoma management is shifting toward earlier, drop-sparing interventions using sustained drug delivery and advanced laser ...

Biotechnology company Optigo Biotherapeutics received the People’s Choice Award at the 2025 Eyecelerator meeting for the ...

Alkeus Pharmaceuticals reveals promising Phase 2 SAGA study results, showing gildeuretinol slows vision decline in geographic ...

Beacon Therapeutics reveals promising interim results for laru-zova, a gene therapy showing potential to improve vision in ...

Machine learning algorithms enhance retinopathy of prematurity screening using smartphone images, expanding access in ...

Mark Loganoff, MD, shared his experience and perspective on the benefits and realities of transitioning to office-based surgery in an interview with the Eye Care Network at the 2025 American Society ...

Katherine Talcott, MD, a retina specialist at Cleveland Clinic, presented findings on EYP-1901 in the phase 2 DAVIO study.

A one-drop, low dose atropine study assesses accommodative amplitude and dynamics, with clinically applicable findings.

Topcon Healthcare launches IDHea, an innovative platform enhancing AI research and ocular data access to improve clinical ...

A study reveals that repeated anti-VEGF injections for AMD do not alter retinal vascular metrics over time, ensuring ...

In cases with optic nerve hyperfluorescence or neurologic symptoms, prompt neuroimaging is warranted to rule out neuro-Behcet ...

ISTH0036 targets TGF-β2, crucial in fibrosis and retinal disease progression, showing promise in the BETTER trial for retinal fibrosis treatment. The trial demonstrated stable or improved visual ...